Categories: Health

Monthly information on share capital and company voting rights

PARIS, July 04, 2025 (GLOBE NEWSWIRE) —

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: Euronext Growth

ISIN code: FR0010425595

Date Total number of shares
in the capital
Total number of voting rights
06/30/2025 100,325,229 89,428,630

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

GlobeNews Wire

Recent Posts

AvironiX Unveils AviSpray-10c, a Backpack-Sized Agricultural Spraying Drone for India’s Precision Farming Sector

CHENNAI, India, Dec. 8, 2025 /PRNewswire/ -- AvironiX Drones, a Chennai-based deep-tech drone company focused on precision farming and defence technologies, today…

55 minutes ago

Abstract and Open World Partner to Launch the First National-Scale Tokenization Engine for the World’s Most Valuable Real-World Assets

For the first time, the world's most strategic assets—AI supercomputing centers, strategic real estate and…

55 minutes ago

Navitas, Cyient Semiconductors enter into a strategic partnership to accelerate GaN adoption in India’s AI, Mobility, Industrial, and Energy Markets

TORRANCE, Calif. and HYDERABAD, India, Dec. 8, 2025 /PRNewswire/ -- Navitas Semiconductor Corporation (Nasdaq: NVTS),…

55 minutes ago

DXC Appoints Russell Jukes as Chief Digital Information Officer to Strengthen Unified Digital Strategy

ASHBURN, Va., Dec. 8, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading enterprise technology and…

55 minutes ago

Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI

Latest release enables faster, more confident design decisions at scale with accelerated simulation, AI-powered, real-time…

55 minutes ago

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin…

56 minutes ago